NORELGESTROMIN
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $955,800 | 1 | 0 |
| 2018 | $115,000 | 4 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.1M | 5 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Study to Evaluate the Cumulative Skin Irritation and Sensitization Potential of a Generic Norelgestromin and Ethinyl Estradiol Transdermal System 15035 mcg per day to that of Xulane Transdermal System in Normal Healthy Adult Human Female Subjects under Fasting Conditions | Amneal Pharmaceuticals LLC | $955,800 | 0 |
| A Study to Evaluate the Skin Irritaiton of a Test Norelgestromin and Ethinyl Estradiol Transdermal System 15035 mcg per day Amneal Pharmaceuticals LLC to Xulane norelgestromin and ethinyl estradiol transdermal system 15035 mcg per day Mylan Pharmaceuticals Inc. - 11849703 | Amneal Pharmaceuticals LLC | $115,000 | 0 |
Top Doctors Receiving Payments for NORELGESTROMIN
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Pittsburgh, PA | $1.1M | 5 |
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.1M
- Total Doctors 0
- Transactions 5
About NORELGESTROMIN
NORELGESTROMIN is a drug associated with $1.1M in payments to 0 healthcare providers, recorded across 5 transactions in the CMS Open Payments database. The primary manufacturer is Amneal Pharmaceuticals LLC.
Payment data is available from 2018 to 2019. In 2019, $955,800 was paid across 1 transactions to 0 doctors.
The most common payment nature for NORELGESTROMIN is "Unspecified" ($1.1M, 100.0% of total).
NORELGESTROMIN is associated with 2 research studies, including "A Study to Evaluate the Cumulative Skin Irritation and Sensitization Potential of a Generic Norelgestromin and Ethinyl Estradiol Transdermal System 15035 mcg per day to that of Xulane Transdermal System in Normal Healthy Adult Human Female Subjects under Fasting Conditions" ($955,800).